The scaffolding protein NEDD9 is an established pro-metastatic marker in several cancers.
Introduction
The cytoplasmic docking protein, NEDD9 has emerged as a biomarker of melanoma, pancreatic, and lung cancer metastasis and is required for the migration of tumor cells (1) (2) (3) (4) (5) (6) . The overexpression of NEDD9 leads to mesenchymal protease-dependent migration (4, 7) . NEDD9 promotes epithelial-mesenchymal transition (EMT) and invasion of BCa cells (8) .
Extracellular matrix (ECM) proteolysis is dependent upon soluble and membrane bound matrix metalloproteinases (MMPs) (9) . Membrane bound MMP14 is a key enzyme involved in ECM degradation and invasion of tumor cells. The activity of MMP14 is regulated by phosphorylation, proteolysis, and endocytosis (10) (11) . MMP14 is activated by furin and is inhibited by tissue inhibitor of MMP, TIMP2, which makes a stable complex with the activated MMP14 (12) (13) . The tertiary complex of MMP14, TIMP2, and proMMP2 is required to form on the cell surface to activate MMP2 by a neighboring MMP14 free of TIMP2 (14) . The presence of excess TIMP2 results in inhibition of MMP14 activity and decreased processing of proMMP2 to active MMP2 (15) . In invasive cancer cells, MMP14 is localized at the membrane of invadopodia, ventral actin-based membrane protrusions (16) (17) . Local ECM degradation is initiated upon the assembly of: F-actin, cortactin, N-WASP, and the Arp2/3 complex (17) (18) .
Functional mature invadopodia form when F-actin and cortactin-rich puncta initiate the accumulation of MMP14, thus forming proteolytically active protrusions (16) . Activity of MMP14 is required for invasion of 3D collagen matrices in tissue culture and in nude mice (19) (20) .
While NEDD9 deficient cells are characterized by reduced migration accompanied with reduced levels of Src and FAK kinase activity (21) (22) Author Manuscript Published OnlineFirst on November 7, 2013; DOI: 10.1158/1541-7786.MCR- in BCa has been unclear. Although NEDD9 and another Cas family member, p130Cas, were previously identified in invadopodia of cancer cells (23) (24) (25) , the differences between NEDD9 and p130Cas function in invasion are currently unknown.
In transgenic oncogene driven mammary tumor models such as MMTV-PyVmT or MMTV-Her2/Erb2 genetic ablation of NEDD9 leads to delays in tumor initiation and growth but has a limited effect on metastasis (21) (22) . The tumors arising in MMTV-Her2/NEDD9-/-or PyVmT/NEDD9-/-mice underwent a dramatic mutational selection that overcame the initial requirement for NEDD9. In this context it is difficult to determine the requirement for NEDD9 in metastasis since the selection of alternative signaling pathways happened prior to tumor formation. Also, it is currently unknown what stages of metastasis are affected by NEDD9.
Overexpression of NEDD9 is often mentioned in diverse cancers (1) (2) (3) (4) . However, as of now, a comprehensive analysis of NEDD9 expression with respect to BCa progression has not been conducted; To address these questions, we analyzed NEDD9 protein expression in a tissue microarray (TMA) consisting of 200 progressive BCa patient biopsies and in a panel of diverse BCa cell lines. We found that NEDD9 is overexpressed in invasive breast ductal carcinomas and invasive cell lines. We discovered that NEDD9 is involved in regulation of MMP14 activity on the cell surface, but not expression. Depletion of NEDD9 leads to decrease in proteolytic activity of soluble MMPs and transmembrane MMP14, resulting in the ablation of cancer cell invasion in vitro and in vivo. The decrease in activity was due to the association of MMP14 with its inhibitor TIMP2 on cell surface. Depletion of TIMP2 or MMP14 expression or addition of excess of recombinant TIMP2 to control cells led to a similar phenotype, suggesting that excessive TIMP2 bound to the MMP14 potentially is the primary reason for decreased invasion in carcinoma cells upon depletion of NEDD9. Using inducible shRNAs against NEDD9 in xenograft models, we dissected particular stages of metastasis dependent upon NEDD9 expression and thus define the sensitive stages of tumor progression where anti-NEDD9 therapy could be applied to prevent metastasis. We found that reduction of NEDD9 expression in established tumors leads to a drastic decrease in MMPs activity and number of circulating tumor cells resulting in a decrease in the overall number and size of pulmonary metastases. Collectively, our findings suggest a novel mechanism for NEDD9 in accelerating cell invasion through regulation of MMP14 by TIMP2 thus defining the new therapeutic approach for anti-metastatic strategies via manipulation of NEDD9 expression. Cell lines MDA-MB-231, MDA-MB-453, ZR-75-1, BT-549,   MCF10A, MCF7, AU-565, BT-20, were purchased from and authenticated by American Type Culture Collection (ATCC), MDA-231-LN (Caliper Life Sci.) and grown based on manufacturer's recommendations. shRNA expressing constructs against NEDD9, control (sequences available upon request) and smart pool siRNAs against MMP14 and TIMP2 and siControl were purchased from ThermoFisher Scientific as ready to use siRNAs or in pGIPZ, or in doxycycline-inducible pTRIPZ vectors. Lentiviral particles were prepared as previously described (26) . For rescue experiments wild type cDNA of mouse NEDD9 was subcloned into pLUTZ lentiviral vector under doxycycline-inducible promoter (27) . Cell medium and supplements were purchased from ATCC (Sigma).
MMP Antibody Array. MMP Antibody Arrays were purchased from RayBiotech, Inc. and assays were carried out according to the manufacturer's protocol using whole cell lysate (WCL) and conditioned for 24h serum free medium (SFM). Fluorescent-gelatin degradation assay.
Foci of degraded matrix were visible as dark areas that lack fluorescence in the FITC-gelatin matrix (Life Technologies). Cells with pseudopods were identified by the presence of at least one actin/cortactin aggregate within the cell. Degradation per cell area was analyzed using ImageJ (NIH) as described (16) . At least 100 cells were counted per each experimental condition. Data were pooled from multiple independent experiments. DQ Collagen Assay. Cells expressing doxycycline-inducible shRNAs against NEDD9 and red fluorescent protein (RFP) embedded in DQcollagen I/IV combined with matrigel (BD Biosciences) to allow for cell tracing and dose-dependent manipulation of NEDD9 depletion.
shRNA expression was induced for 72h. DQ collagen I/IV/matrigel assays were carried out according to a previously published protocol (28) . Detailed protocol for data acquisition and analysis outlined in supplementary material.
EnzChek Gellatinase/Collagenese assay. Assay was purchased from Life Technologies and performed accordingly to manufacturer's recommendations using shNEDD9 and shCon conditioned medium (24h). Fluorescence was measured at 485/545mn.
Gelatin zymography. The gelatin zymography protocol was performed as previously described (16, 24) . Briefly, 4ml of 24h conditioned media was collected from cells, concentrated using were pre-blocked with 5mg/ml of Human IgG (Sigma). As a control, non-specific primary antibody, either Rabbit or mouse IgG were used (Sigma).
Western blotting (WB).
Western blotting was done using standard procedures (26, 30) . Primary antibodies included mouse anti-NEDD9 mAb (2G9) (29) , anti-phTyr, (Cell Signaling Technology Inc.), anti-p130Cas, -MMP2, -MMP9, -GAPDH, -RFP (ThermoFisher), anticortactin, -MMP14 (Novus), anti-β-actin, -α-tubulin, (Sigma) antibodies. Secondary HPRconjugated antibodies and chemiluminescence-based detection and quantification methods were previously described (30) .Recombinant TIMP2 titration assay. Recombinant human TIMP2 was purchased from Life Technologies, diluted in cell culture medium and added to the cells in 0-100nM final concentration for 6-12h. After indicated times cells number of invaded cells was calculated as described in Boyden chamber invasion assay.
Immunofluorescence (IF)
. IF was performed as previously described (30 Virginia University. TMA sections were deparaffinized, endogenous peroxidase activity was quenched with 3% hydrogen peroxide, and slides were incubated with anti-NEDD9 antibodies (1:100 dilution) overnight at 4C; followed by staining with secondary peroxidase-labeled antibodies and developed with DAB (DAKO). Positive and negative controls were included with each run. Staining was done in duplicate. The IHC analysis and scoring protocol is available in Supplementary materials.
Lung metastasis analysis.
Lungs were collected and fixed in 4%PFA for 24-48h embedded in paraffin by WVU Tissue Bank as previously described (30) . Serial 6-10μm think sections were cut at each 40μm steps through the whole organ. Sections were subjected to hematoxylin and eosin (H&E) staining. Metastatic lesions were visually identified and images were acquired using Zeiss Axioplan microscope with x4 and x10 NA1.6 objective, followed by higher x100 magnification evaluation of whole section. Multiple sections from each lung/mouse were analyzed in each cohort. Quantification of the metastases was done by WVU pathologist (Dr. Statistical Analysis. Statistical comparisons were made using two-tailed Student's t test. When more than two groups were analyzed, one-way analysis of variance (ANOVA) was used. P≤0.05 was considered to be significant. Experimental values were reported as the means with +/-S.E.M.
All calculations were made using the GraphPad InStat software. Random forests analysis provides an aggressive machine learning approach for classifying data into groups using ensembles of regression trees. Using this approach, we quantified the influence of NEDD9 IHC intensity staining in prediction of disease stage by the construction of the regression trees using a variable importance score averaged over all the trees.
Results
Increase in NEDD9 protein correlates with an invasive state in BCa. To assess the role of NEDD9 in cancer progression, we screened two independent TMAs using immunohistochemical staining (IHC) comprised of 200 BCa cases. Figure 1A shows representative images of NEDD9 staining in normal, DCIS (ductal carcinoma in situ), IDC (invasive ductal carcinoma), and MIDC-LN (metastatic invasive ductal carcinoma, lymph node). Statistical analysis of anti-NEDD9 staining intensity performed either by automated image capture system (Fig.1B) or visual evaluation by pathologist (Suppl. Fig.1A ) suggests that NEDD9 levels positively correlate with disease progression. The lowest intensity was found in normal tissue, followed by a 10 fold increase in DCIS and a 30 fold increase in IDC, whereas only a 10 fold increase in expression was observed in MIDC-LN (Fig.1B) . Random forest statistical analysis of NEDD9 staining, which achieved an out-of-bag error rate of 0.49, indicates that by using NEDD9 protein levels, one can double the predictive power over chance of classifying tumor. The independent prognostic value of NEDD9 expression had 70% probability of identifying cases of IDC (Fig.1C ). confirmed these findings using FITC-gelatin degradation assays. Representative images and quantification of degradation by MCF7, BT-549 and ZR-75-1 shown in Figure 1F -G and Suppl. Fig.1B . In contrast to the highly invasive MDA-MB-231 and BT-549, the AU-565 and MCF7 BCa cells were not proficient in gelatin degradation. We and others previously noticed that these cells expressed low levels of cortactin (Fig.1D) , MMP14, and MMP2 (33) which are required for invasion (16) . This indicates that NEDD9 is required to support ECM degradation, although other components of the invasion machinery are also required for these processes.
NEDD9 expression in

NEDD9 localizes to and promotes invadopodia maturation.
To define the requirement of NEDD9 in formation and function of invadopodia , we infected MDA-MB-231, BT-549, and ZR-75-1 cells with two different shRNAs targeting NEDD9, which did not effect the expression of p130Cas (Fig.2A ). Cells were plated on FITC-gelatin coated coverslips and co-stained with invadopodia markers F-actin and cortactin to visualize the area of gelatin degradation and pseudopods ( Fig.2B-C) . Depletion of NEDD9 led to a two-threefold reduction in the number of cells degrading matrix, while viability of cells was not affected (Fig.2D) . Interestingly, NEDD9 depleted cells had a similar number of F-actin/cortactin rich puncta (Fig.2E ) which are found during the initial stages of invadopodia formation (16) but show an absence of degradation beneath the puncta (Fig.2C) . p130Cas, which is highly expressed in BCa cells (Fig2A), was not able to compensate for the decrease in NEDD9 under current experimental settings suggesting a critical role of NEDD9 in invadopodia based invasion in BCa. The localization of other major components of invadopodia, such as: Arp3 and N-WASP, were not affected by depletion of NEDD9 (Suppl. Fig.1C ). 
To determine if NEDD9 localized to invadopodia in BCa cells, we co-stained cells with anti-NEDD9 antibodies (29) and invadopodia markers (16) . We found that NEDD9 was consistently co-localized with cortactin, actin, and phTyrosine ( Fig.2F-G (Fig.4A-B 
deficiency in the activity of secreted collagenases (Fig.4C ). Next, we tested the activity of secreted MMPs by gel zymography. The activity of MMPs, particularly MMP2 and MMP9, was reduced by 60-80% upon NEDD9 depletion (Fig.4D-E) , indicated by the decrease in the amount of active 68kDa form of MMP2 (Fig.4D, quantification of 68kDa form Fig.4E ) and 92-86kDa forms of MMP9 (Fig.4E) . We then tested the activity of MMP14 using a MMP14-specific fluorogenic substrate and show that NEDD9 depletion results in a significant decrease in MMP14 activity (Fig.4F) .
NEDD9 depletion leads to inactivation of MMP14 by TIMP2. Membrane bound MMP14 is one of the key molecules involved in activation of soluble MMPs and pericellular degradation (34) . Total MMP14 protein level (Fig.5A ) and localization patterns (Suppl. Fig.2C) were not impacted by NEDD9 depletion. Interestingly, cell surface levels of MMP14 and TIMP2 proteins assessed by FACS (Fig.5B-C) and IF (Fig.5D-E) had increased up to 40% upon NEDD9 depletion. Note, that according to the MMP array analysis performed earlier depletion of NEDD9 did not affect total expression or secretion of TIMP2 (Fig.4A-B ).
TIMP2 is a well-known regulator of MMP14 and MMP2 activity. An increased amount of TIMP2-bound MMP14 is indicative of its decreased activity (35) (36) . Depletion of MMP14 (Fig.6A ) and TIMP2 in BCa cells (Fig.6B) , using specific siRNAs, resulted in a similar to shNEDD9 invasion deficiency (Fig.6C) suggesting that MMP14 and TIMP2 are potentially the downstream targets affected by NEDD9. Moreover, addition of increasing amounts of recombinant TIMP2 to the medium of control cells leads to a similar inhibition of invasion at the higher concentrations of TIMP2 (Fig.6D) . Importantly, re-expression of NEDD9 (Fig.6E) on restored the amount of surface-bound MMP14 (Fig.6F ) and invasion proficiency of shNEDD9 cells (Fig.6G ). (Fig.7C- shRNA-Day0). Analysis of peripheral blood samples for CTCs reveals similar number in all three cohorts of animals (shCon/shN1/shN4) (Fig.7D-shRNA-Day0) , as well as similar number of metastases seeded in the lungs (Fig.7E-shRNA-Day0 ). NEDD9 depletion during the following 14 days in established primary tumors and metastases led to a drastic decrease in the number of CTCs (Fig.7D-shRNA-Day14 ) and number of metastases in lungs (Fig.7E-F-shRNA-Day14 ).
NEDD9 depletion inhibits invasion and intravasation of tumor cells from primary
The primary tumors had continued to grow during the shRNA induction based on BLI data 
Discussion
While recent studies have established NEDD9 as an essential factor for invasion (2-4) and metastasis (1, 37) the precise mechanism of how NEDD9 functions and its contribution to various stages of metastasis have been poorly defined. In our current study we show that NEDD9 is upregulated in breast tumors, and specifically increases in IDC, giving NEDD9 the potential to serve as a strong diagnostic marker for invasive tumors.
Interestingly, NEDD9 is decreased in metastatic samples suggesting that high level of NEDD9 is required during the invasion from the primary site, most probably to enable protease-dependent degradation of the basal membrane and EMT re-programming. While still increased compared to normal tissue, lesser amounts of NEDD9 are sufficient during growth at distant metastatic sites.
Alternatively, upon arrival at distant sites, a decrease in NEDD9 expression might be beneficial in order to undergo mesenchymal to epithelial transition to establish the colony (8) . This data is in accordance with the previously published studies showing that established metastasis in lungs had less NEDD9 when compared to primary tumor (6) (7) (21) (22) . It is possible that decrease in NEDD9 might be beneficial for migration through filamentous collagen rich matrices; while in the basal membrane like matrix, the presence of NEDD9 was an absolute requirement for efficient invasion. In a search for a molecular mechanisms underlying NEDD9 dependent invasion, we found that depletion of NEDD9 does not affect formation of nascent invadopodia, characterized by aggregation of F-actin, cortactin, and MMP14 (17) , but prevents further maturation of invadopodia into proteolytically active structures (16) . These findings are in agreement with previous report in SCC-9 cells where NEDD9 expression was required for matrix degradation, but disagree with regard of NEDD9 requirement for invadopodia formation (23) . The differences might be associated with artificial exogenous overexpression of NEDD9 in SCC9 cells. The source of differences could also reside in tissue specific behavior of breast versus head and neck cells. It is also needs to be noted that another NEDD9 family member protein p130Cas was previously identified in invadopodia (24) . In the cell lines used in our study depletion of NEDD9 did not affect the formation of invadopodia, indicating the different roles of these adaptor proteins in invasion. shC on shN1 shN4
